RT Journal Article
SR Electronic
T1 Neural mechanisms of disease pathology and cognition in young-onset Alzheimer’s Disease variants
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.03.11.24304042
DO 10.1101/2024.03.11.24304042
A1 Sacu, Seda
A1 Slattery, Catherine F.
A1 Friston, Karl J.
A1 Paterson, Ross W.
A1 Foulkes, Alexander J.M.
A1 Yong, Keir
A1 Crutch, Sebastian
A1 Schott, Jonathan M.
A1 Razi, Adeel
YR 2024
UL http://medrxiv.org/content/early/2024/07/23/2024.03.11.24304042.abstract
AB Late-onset Alzheimer’s disease is consistently associated with alterations in the default-mode network (DMN)—a large-scale brain network associated with self-related processing and memory. However, the functional organization of DMN is far less clear in young-onset Alzheimer’s disease (YOAD). We assessed resting-state DMN effective connectivity in two common YOAD variants (i.e., amnestic variant (n = 26) and posterior cortical atrophy (n = 13) and healthy participants (n=24) to identify disease- and variant-specific connectivity differences using spectral dynamic causal modelling. Patients with the amnestic variant showed increased connectivity from prefrontal cortex to posterior DMN nodes relative to healthy controls, whereas patients with posterior cortical atrophy exhibited decreased posterior DMN connectivity. Right hippocampus connectivity differentiated the two patient groups. Furthermore, disease-related connectivity alterations were also predictive of group membership and cognitive performance. These findings suggest that resting-state DMN effective connectivity provides a new understanding of neural mechanisms underlying the disease pathology and cognition in YOAD.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe YOAD study was funded by Alzheimer's Research UK through a generous donation from Iceland Foods. AR and KJF are affiliated with The Wellcome Centre for Human Neuroimaging, supported by core funding from Wellcome [203147/Z/16/Z]. AR is a CIFAR Azrieli Global Scholar in the Brain, Mind & Consciousness Program. JMS acknowledges the support ofthe National Institute for Health Research University College London Hospitals Biomedical Research Centre, Wolfson Foundation, Alzheimer's Research UK, Brain Research UK, Weston Brain Institute, Medical Research Council, British Heart Foundation, UK Dementia Research Institute and Alzheimer's Association. A.R. is funded by the Australian Research Council (Ref: DP200100757) and the Australian National Health and Medical Research Council (Investigator Grant 1194910). RWP acknowledges support from the National Institute for Health Research University College London Hospitals Biomedical Research Centre, the Alzheimer's Association. SC acknowledges the support of the Economic and Social Research Council and National Institute for Health Research (ESRC/NIHR ES/L001810/1). K. Y. is an Etherington PCA Senior Research Fellow and is funded by the Alzheimer's Society, grant number 453 (ASJF/18/003).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the National Hospital for Neurology and Neurosurgery Research Ethics Committee. All participants provided written informed consent.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThe data that support the findings of this study are available from the corresponding author, upon reasonable request.